Table 2. VZV disease in the 2 study... | American Society of Hematology

Table 2.

VZV disease in the 2 study groups

VZV	Acyclovir, no. (%)	Placebo, no. (%)	HR	95% CI	P
By year 1^*	2 (5)	10 (26)	0.16	0.035, 0.74	.006
By year 2	8 (21)	12 (31)	0.52	0.21, 1.3	.15
By year 3	11 (29)	13 (33)	0.65	0.29, 1.5	.30
By year 5†	14 (37)	14 (36)	0.76	0.36, 1.6	.46

VZV	Acyclovir, no. (%)	Placebo, no. (%)	HR	95% CI	P
By year 1^*	2 (5)	10 (26)	0.16	0.035, 0.74	.006
By year 2	8 (21)	12 (31)	0.52	0.21, 1.3	.15
By year 3	11 (29)	13 (33)	0.65	0.29, 1.5	.30
By year 5†	14 (37)	14 (36)	0.76	0.36, 1.6	.46

Shown are results from the intent-to-treat analysis and among patients who received at least 30 days of study drug.

HR indicates hazard ratio; CI, confidence interval.

Year refers to year after transplantation

One additional case occurred in each group between 6 and 10 years after transplantation